Hotline: 1800 102 2007
Hotline: 1800 102 2007
Search Business Opportunities
Planning 2015-04-29

Pharma major Sun Pharma may spend $7bn on further acquisitions

Soon after acquiring its domestic rival Ranbaxy Laboratories, Pharma major Sun Pharmaceuticals Industries Ltd is keen to spend another $7 billion to satisfy its craving for more takeovers.

Pharma major Sun Pharma may spend $7bn on further acquisitions

Emboldened by its takeover of domestic rival Ranbaxy Laboratories, India's leading Pharma company Sun Pharmaceuticals Industries Ltd is willing to spend as much as $7 billionon further acquisitions

The biggest deal till date at $3.2 billion, the Ranbaxy deal of Sun Pharma has given it sufficient scale in generics and emerging markets to think about its next step - beefing up expertise in higher margin products and gaining a bigger global presence.

As per the latest findings of leading business dailies, next on Sun Pharma's radar are US and European companies that develop bio-similars and cheaper copies of biotech drugs, which have become some of world's hottest selling medicines.

Dilip Shanghvi, who controls Sun Pharma with his scions and is India's second richest man as per the globally renowned Forbes magazine, feels the need for a ‘transformational acquisition’, but will be patient about finding the right candidate, said sources.

The Sun Pharma, which has a present market value of about $36 billion, is also interested in non-biotech complex generic medicines that offer better margins than the copied drugs specialised by Indian drugmakers.

Reportedly, the Pharma major is willing to look at either whole companies or acquire complex generics on their own, declining to be identified as they were not authorized to speak to the media on the matter.

In one potential near-term opportunity, Sun Pharma may emerge as a bidder for some drugs Teva Pharmaceutical Industries, the world's biggest generic drugmaker, will likely be required to divest if it is successful in its unsolicited $40 billion bid for rival Mylan.

With a cash balance of $1.5 billion and a debt-to-equity ratio of just 0.13, Sun Pharma would find it easy to take on debt to fund any large acquisition.

Related opportunities
  • Multi Cuisine Restaurant
    About Us: Shaking up the traditional food & drink space with..
    Locations looking for expansion Gujarat
    Establishment year 2004
    Franchising Launch Date 2018
    Investment size Rs. 1 Cr. - 2 Cr
    Space required 3000
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Ahmedabad Gujarat
  • Juices / Smoothies / Dairy parlors
    About Us: MilkyWay, a venture of Chanda Softy Ice Creams, started..
    Locations looking for expansion Hydrabad
    Establishment year 1994
    Franchising Launch Date 2018
    Investment size Rs. 10lac - 20lac
    Space required 180
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater hyderabad Hydrabad
  • Bars, Pubs & Lounge
    About Us: Barf Soda Paani An Upcoming Concept Pub cum Restro Bar Based..
    Locations looking for expansion West bengal
    Establishment year 2017
    Franchising Launch Date 2019
    Investment size Rs. 1 Cr. - 2 Cr
    Space required 2200
    Franchise Outlets -NA-
    Franchise Type Unit
    Headquater Saltlake West bengal
  • Mobile Application Services
    About Us: Rubix 108 Technologies , is a unique combination of..
    Locations looking for expansion Maharashtra
    Establishment year 2012
    Franchising Launch Date 2015
    Investment size
    Space required -NA-
    Franchise Outlets -NA-
    Franchise Type MultiUnit
    Headquater Pune Maharashtra
Insta-Subscribe to
The Franchising World
For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you
OR Click here to Subscribe Online
Daily Updates
Submit your email address to receive the latest updates on news & host of opportunities
More Stories

Free Advice - Ask Our Experts